Provides Amgen access to Nuevolution’s proprietary Chemetics® drug discovery
platform to identify and develop novel therapeutics

Nuevolution is eligible to receive up to USD 410 million per development program
and tiered royalties on future sales

Amgen has the exclusive option to obtain all rights to successfully developed
programs
Stockholm, 4 October, 2016. Nuevolution AB (publ) (NUE.ST) announced today that
Amgen and Nuevolution have entered into a multiple target research collaboration
to develop and commercialize novel therapeutics in the areas of oncology and
neuroscience. Nuevolution will apply its Chemetics® drug discovery platform to
discover and advance potential therapeutics of interest to Amgen. The research
collaboration brings together Nuevolution’s proprietary drug discovery platform
with Amgen’s disease expertise and drug development capabilities.

Under the terms of the agreement, Amgen has an exclusive option to obtain all
rights to successfully developed programs. Nuevolution is eligible to receive a
license fee payment upon option exercise and milestone payments upon achievement
of specified research, development and commercial milestones, amounting up to
USD 410 million per target. Nuevolution would also be entitled to receive
royalties on future sales. Additional financial details are not being disclosed.

Nuevolution will be responsible for the early research phase and Amgen will work
collaboratively with Nuevolution during late-stage research. Amgen will be fully
responsible for preclinical development, clinical development and
commercialization worldwide.

“We are excited about entering into this broad collaboration with Amgen,” said
Alex Gouliaev, CEO of Nuevolution A/S and continued, “the agreement with Amgen
represents an important business component for Nuevolution in its ambition to
discover and develop new medicines for severe diseases, while also capitalizing
on Nuevolution’s powerful drug discovery engine. We are looking forward to an
excellent working relationship with Amgen’s dedicated research and development
teams.”

“Amgen is pleased to enter this agreement with Nuevolution to leverage their
platform to identify small molecule compounds for targets that are difficult to
drug using conventional methods,” said Alexander Kamb, Ph.D., senior vice
president of Discovery Research at Amgen. “DNA-encoded screening platforms such
as Nuevolution’s allows for rapid screening of billions of compounds to help
bring important therapies to the clinic faster and with increased precision.”

For more information, please contact:

Alex Haahr Gouliaev

Chief Executive Officer

Nuevolution AB (publ)

Phone: +45 7020 0987

Email: ahg@nuevolution.com

Henrik D. Simonsen

Chief Financial Officer

Nuevolution AB (publ)

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused on
therapeutically important targets within inflammation, oncology and immuno
-oncology.

This information is information that Nuevolution AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities Market Act.
The information was sent for publication on Tuesday 4 October, 08:45 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com